Form 4 Filing for Avalo Therapeutics, Inc.

On June 2, 2026, Aaron Kantoff, a director at Avalo Therapeutics, Inc., was granted a stock option to acquire 20,100 shares of the company's Common Stock at an exercise price of $13.96 per share. This option vests fully on June 2, 2027, provided Mr. Kantoff continues his service as a director. The option has an expiration date of June 2, 2036. The transaction is reported on Form 4, indicating a change in beneficial ownership. Mr. Kantoff acquired these options, as indicated by the 'A' transaction code. Following this grant, Mr. Kantoff's post-transaction shares in this option grant are 20,100.